1. Introduction {#s0005}
===============

Schizophrenia and Autism Spectrum Disorder (ASD) are pervasive neurodevelopmental conditions, presenting common features, both characterized by a chronic clinical course ([@bb0200]; [@bb0215]).

Although the current nosography describes schizophrenia and ASD as distinct conditions ([@bb0015]), literature highlights some overlapping features between them ([@bb0020]; [@bb0115]; [@bb0205]). The observation of impairments in cognitive, social cognitive, functional domains ([@bb0100]; [@bb0200]; [@bb0215]), and physiopathologic mechanisms suggests that ASD and schizophrenia may share similar defects in biological pathways of brain development, suggesting a disorders\' phenotypic spectrum ([@bb0080]; [@bb0195]).

Noteworthy, recent research has identified a specific subgroup of patients affected by schizophrenia that reveal autistic traits (ATs), showing serious dysfunctions of social interactions, communication, emotion processing and motor abnormalities ([@bb0025]; [@bb0165]; [@bb0180]). Moreover, patients with ATs show a peculiar clinical ([@bb0025]), functional ([@bb0120]) as well as cognitive profile ([@bb0025]; [@bb0115]; [@bb0180]; [@bb0205]). In particular, patients with ATs present a longer duration of illness ([@bb2050]; [@bb0100]), more severe negative symptoms ([@bb0025]; [@bb0235]) and an earlier disease onset ([@bb0105]; [@bb0160]a). Their neurocognitive profile is characterized by more pronounced deficits in working memory, executive functions, and processing speed ([@bb0120]). Regarding functioning, results are still divergent: some studies report a more compromised social functioning in patients with ATs ([@bb0120]), while others do not show this evidence ([@bb0105]; [@bb0240]).

To our knowledge, literature does not offer data regarding social cognitive performance in patients with ATs. Nevertheless, it is well known that a severe impairment in social cognitive abilities, especially in Theory of Mind (ToM, i.e., the ability to attribute mental states to other individuals) is a core and overlapping cognitive symptom ([@bb0140]), and it is related to similar neural abnormalities in the medial prefrontal and the superior temporal sulcus in both ASD and schizophrenia ([@bb0065]; [@bb0260]). Many patients affected by schizophrenia show compromised ToM abilities after their illness onset and this is considered one of the main factor causing daily functioning impairment ([@bb0135]; [@bb0245]). Moreover, ToM deficit is widely heterogeneous in schizophrenia. Indeed, although many patients get a poor performance on ToM tasks, a non-negligible group of subjects displays a quite normal or close to normal performance on mentalizing tasks ([@bb0055]; [@bb0075]; [@bb0230]). Therefore, we may hypothesize that ToM heterogeneity among patients with schizophrenia may be linked to ATs, since the degree of ToM impairments may be higher in patients with ATs. In line with this hypothesis, the study of ToM functioning in patients with ATs could represent a central issue and may open new debates about this clinical subgroup.

Given the main role of ToM impairment, innovative interventions have been developed in order to improve ToM abilities and, consequently, daily functioning in schizophrenia ([@bb0030]; [@bb0035]; [@bb0145]; [@bb0210]; [@bb0225]). Literature demonstrated trainings\' effectiveness in enhancing ToM ([@bb0190]; [@bb0250]) and showed the generalization of ToM gain on daily, social and work functioning ([@bb0040]; [@bb0050]; [@bb0220]). Moreover, Eack and colleagues demonstrated that the benefit achieved in daily functioning after ToM trainings is maintained for at least one year ([@bb0130]; [@bb0060]). Although research showed the effectiveness of the different interventions on ToM in schizophrenia, the size of improvement is variable, from small to moderate mean effect sizes (d: 0.46, 95% CI: 0.15--0.78) ([@bb0185]). We can suggest that the presence of ATs may be a contributing factor to the great variance in ToM improvement. Nevertheless, to our knowledge, no studies explored the impact of social cognitive trainings in patients with ATs in order to establish if autistic features may be a limiting factor of rehabilitation efficacy.

Given this scenario, the current study is two-fold. First, it aims to estimate differences between patients with and without autistic features, on demographic and clinical features, cognitive and ToM abilities as well as on daily and premorbid functioning in a sample of patients affected by schizophrenia. Then, it aims to evaluate the efficacy of a ToM training in patients with ATs compared to patients without ATs.

2. Materials and methods {#s0010}
========================

2.1. Participants {#s0015}
-----------------

We enrolled ninety-six outpatients with schizophrenia. All patients met DSM-5 criteria for schizophrenia, as determined by trained psychiatrists using clinical interviews, and did not present relapse or hospitalization in the past 6 months. All patients underwent a ToM training (see [@bb0040]). Exclusion criteria were: co-morbid psychiatric diagnoses, substance dependence or abuse in the past year, perinatal trauma and major neurological illness.

All subjects provided a written informed consent to a protocol approved by the local Ethical Committee, which followed the principles of the Declaration of Helsinki.

2.2. Design {#s0020}
-----------

Before ToM training (see ([@bb0040])), all enrolled patients were assessed for cognition, intellectual level, ToM, ATs, premorbid and current daily functioning and, after the training, they were re-assessed for ToM abilities.

2.3. Assessments {#s0025}
----------------

ATs severity was assessed with the PANSS Autism Severity Score (PAUSS) ([@bb0165]). Three scores are derived from the sum of specific items of the PANSS: a "Difficulties in Social Interaction" Score (items 1 'blunted affect', 3 'poor rapport', and 4 'social withdrawal' from the Negative Scale); a "Difficulties in Communication" Score (items 5 'difficulties in abstract thinking', and 6 'lack of spontaneity and flow of conversation' from the Negative Scale); and a "Stereotypies/Narrowed Interests" Score (item 5 'mannerism' and 15 'preoccupation' from the General Scale, and item 7 'stereotyped thinking' from the Negative Scale). PAUSS is a reliable tool for the measure of autistic traits in patients; indeed constructs and criterion-related validity of the task were first assessed in a sample of high-functioning ASD patients ([@bb0165]). Patients were not assessed with full PANSS, but they were evaluated only with the PAUSS. The scale has been used to provide a measure of autistic features among patients with schizophrenia ([@bb0025]; [@bb0165]).

Cognition was assessed with the Italian version of the Brief Assessment of Cognition in Schizophrenia (BACS) ([@bb0010]; [@bb0170]), assessing verbal memory, working memory, psychomotor speed and coordination, processing speed, verbal fluency and executive functions.

Intellectual level was assessed by means of the Wechsler Adult Intelligence Scale--Revised (WAIS-R) Italian Version ([@bb0265]). WAIS-R estimates the intelligence quotient (IQ) and its both verbal and performance components.

ToM abilities were assessed with the ToM Picture Sequencing Task (PST) ([@bb0070]) which is composed by a Sequencing Task (i.e., a measure of affective ToM processes) and a Questionnaire (i.e., a measure of cognitive ToM). A previous study by Bechi and colleagues ([@bb0030]) confirmed the reliability and the good internal consistency (Cronbach\'s α coefficient = 0.86). The variables of interest were: First Order Beliefs Total Score, Second Order Beliefs Total Score, Third Order False Beliefs Score, Total Questionnaire Score, Total Sequencing Score, and Total Score.

Premorbid functioning was assessed with the Premorbid Adjustment Scale (PAS) ([@bb0085]), a retrospective interview focused on the individual\'s social and academic achievements preceding illness onset. The PAS assesses premorbid adjustment (PA) during childhood (up to 11 years), early adolescence (12 to 15 years), late adolescence (16 to 18 years) and adulthood (19 years and above). Five domains are assessed (i.e., sociability and withdrawal, peer relationships, scholastic performance, adaptation to school and social-sexual functioning) and rated from 0 (normal adjustment) to 6 (severe impairment).

Functioning was assessed with the Quality of Life Scale (QLS) ([@bb0150]), a 21-items semi-structured interview, balancing subjective questions regarding life satisfaction and objective indicators of social and occupational role functioning. As in previous studies ([@bb0045]; [@bb0090]), we analyzed three subscores: Interpersonal relations (items 1--8), Instrumental role (items 9--12), Personal autonomy (items 13--2).

All tasks were administered by trained psychologists, except for the PAUSS, which was administered by trained psychiatrists. All data were collected at patients\' enrollment.

2.4. Intervention {#s0030}
-----------------

The ToM Intervention consists of five modules divided into 18 sessions (1-h session, twice a week), using comic strips, cartoons and clips depicting human social interactions. The modules were executed in an ascending order of complexity, with the first three modules focusing on cognitive ToM and the last two on affective ToM. Patients were request to recognize mental states and emotions, in order correctly comprehended ToM. A guided discussion of hypotheses follows each session (see more details in [@bb0040]).

2.5. Data analysis {#s0035}
------------------

In line with the previous literature ([@bb0120]; [@bb0165]), we set a PAUSS cut-off score of 30, in order to compare patients with and without ATs. This cut-off yields a specificity of 95%, leading to consider patients with PAUSS \> 30 as patients with ATs (ATs+ group) ([@bb0165]).

Analyses of variance (ANOVAs) were performed on demographic, clinical, cognitive, intellectual, ToM (at T0), functional and premorbid variables, in order to evaluate differences among patients\' groups (ATs+ group and ATs− group).

The size of changes, in each PST subdomains and Total Score, were estimated using Cohen\'s d effect sizes ([@bb0110]).

Pre- to post-treatment changes between groups were analyzed with repeated-measures ANOVA (2 × 2, *p* \< .05, two-tailed) entering ToM measures (i.e., PST total score at T0 and T1) as dependent variables, time as within subjects factor, and patients\' group (i.e., ATs+ group and ATs− group) as independent variable. Fisher LSD post hoc test followed.

3. Results {#s0040}
==========

[Table 1](#t0005){ref-type="table"} shows demographic and clinical characteristics of the sample.Table 1Demographic and clinical characteristics of the sample.Table 1MeanStandard deviation (SD)Age (years)45.51±11.11Education (years)11.71±2.82Age at onset (years)23.91±6.30Duration of illness (years)21.51±9.86Sex (% male)68.22--PAUSS -- difficulties in social interaction10.44±3.59PAUSS -- difficulties in communication6.30±2.99PAUSS -- stereotypies/narrowed interests9.31±4.71PAUSS -- total score26.05±10.63[^2]

Seventy-three patients (76.04% of the total sample) showed a PAUSS Total Score \< 30 (ATs− group), while 23.95% (23 patients) had a PAUSS Total Score \> 30 (ATs+ group).

[Table 2](#t0010){ref-type="table"} summarizes ANOVAs results. Significant between groups differences emerged in many areas. ATs+ group presented an earlier age of onset and a longer duration of illness. Concerning cognitive abilities, ATs+ group had a more impaired cognitive functioning, characterized by a lower intellectual level and more impaired performances in working memory, verbal memory, processing speed and executive functions tasks. As for ToM, ATs+ group resulted more impaired than ATs− group in PST Total Questionnaire Score and Total Score. Differences between groups were also found for premorbid functioning, indeed patients with ATs presented a more impaired premorbid functioning, especially during childhood and adolescence. As for actual daily functioning, ATs+ group resulted more impaired than ATs− group in QLS Self-directedness Score and Total Score.Table 2ANOVA of demographical, clinical, cognitive, ToM, functional variables in both groups.Table 2ATs+ groupATs− groupANOVAMean (SD)Mean (SD)F*p*Age (years)45.30 (±12.42)45.40 (±10.73)0.001.97Education (years)11.26 (±2.43)11.84 (±2.95)0.716.39Age at Onset (years)20.09 (±2.91)25.05 (±6.65)12.055.0008\*Duration of illness (years)25.21 (±12.59)20.34 (±8.61)4.421.03\*Sex (% male)52.1765.75PST (T0) First Order Beliefs Total Score3.30 (±1.55)3.82 (±1.08)3.202.07 Second Order Beliefs Total Score3.13 (±1.18)3.51 (±1.32)1.485.22 Third Order False Beliefs1.17 (±0.83)1.49 (±1.00)1.914.16 Total Questionnaire Score14.70 (±4.09)16.68 (±3.94)4.370.03\* Total Sequencing Score21.96 (±7.08)25.41 (±7.44)3.858.052 Total Score36.65 (±10.13)42.10 (±10.06)5.103.02\*I.Q. Verbal score81.35 (±10.49)90.26 (±14.02)6.817.01\* Performance score75.95 (±10.00)84.53 (±13.43)6.903.01\* Total score78.81 (±9.53)86.58 (±12.99)6.388.01\*BACS Verbal memory30.74 (±12.53)36.58 (±10.05)5.208.02\* Working memory13.43 (±4.30)16.55 (±3.35)12.971.0005\* Psychomotor speed and coordination66.52 (±17.39)68.87 (±15.73)0.348.55 Verbal fluency35.00 (±13.57)36.96 (±13.39)0.370.54 Processing speed31.96 (±13.13)37.49 (±10.14)4.414.03\* Executive functions10.04 (±3.95)13.37 (±3.83)12.904.0005\*PAS Childhood0.46 (±0.18)0.32 (±0.17)7.584.007\* Early adolescence0.51 (±0.14)0.38 (±0.16)7.338.008\* Late adolescence0.55 (±0.12)0.46 (±0.18)3.621.06 Adulthood0.50 (±0.24)0.42 (±0.22)1.442.23 General score0.51 (±0.11)0.49 (±0.13)0.237.62 Total score0.48 (±0.07)0.39 (±0.11)8.307.005\*QLS Relationships16.70 (±8.68)19.41 (±6.75)2.205.14 Work3.30 (±4.77)3.20 (±4.77)0.007.93 Self-directedness19.20 (±9.41)26.77 (±7.98)12.983.0005\* Total score39.20 (±20.90)49.38 (±14.64)6.178.01\*[^3][^4][^5][^6]

Effect-sizes of improvements on PST subscales and Total Score in both groups are depicted in [Table 3](#t0015){ref-type="table"}.Table 3Effect-sizes of improvements on PST in both groups.Table 3ATs+ groupATs− groupMean (SD)Mean (SD)PST First Order Beliefs Total Score0.16 (±1.11)0.30 (±0.98) Second Order Beliefs Total Score0.03 (±1)0.53 (±1.08) Third Order False Beliefs0.21 (±1.21)0.45 (±1.24) Total Sequencing Score−0.04 (±0.86)0.33 (±0.89) Total Questionnaire Score0.02 (±1.01)0.49 (±0.98) Total Score−0.02 (±0.91)0.42 (±0.87)[^7][^8]

Repeated-measures ANOVA showed significant time (pre vs post treatment) × group (ATs+ group and ATs− group) interactions on PST Total Score (F(1, 94) = 4.57, *p* = .03). As revealed by Fisher LSD post hoc test, ATs− group improved significantly from pre to post treatment (T0-T1), while ATs+ group did not (see [Table 4](#t0020){ref-type="table"}).Table 4Repeated measures ANOVA on ToM.Table 4ATs+ groupATs− groupTG × T*p* (T0-T1)*p* (T0-T1)F*p*F*p*PST -- Total Score.89\<.0001[⁎](#tf0005){ref-type="table-fn"}3.66.0594.57.03[⁎⁎](#tf0010){ref-type="table-fn"}[^9][^10][^11][^12]

4. Discussion {#s0045}
=============

The present study was conceived to identify cognitive, sociocognitive and functional differences between patients with and without ATs, and to evaluate the different efficacy of ToM training in these two groups.

Our work supports previous literature, showing that there is a subgroup of patients with ATs ([@bb0025]; [@bb0120]), characterized by a more deficitary cognitive, sociocognitive and functional profile. This is the first study that observed a more limited ToM improvement after a socio cognitive training in patients with ATs.

In detail, the use of the cut-off of PAUSS Total Score at 30 allowed to identify patients with ATs (23.95% of the sample) and without ATs. Our results confirm the rates found in previous studies for ATs in schizophrenia, which are highly variable, from 0.78% to 61% ([@bb0100]; [@bb0175]), according to the assessment employed.

As demonstrated in literature ([@bb0025]; [@bb0100]; [@bb0160]), ATs+ group is characterized by a significant earlier onset of the disease and a longer illness duration. As for cognition, ANOVA showed significant differences between groups in I.Q. (Verbal, Performance and Total Scores), verbal memory, working memory, processing speed, and executive functions. Thus, ATs+ group showed a more severe impairment in cognitive abilities, which affects specific domains, as already seen in previous works ([@bb0025]; [@bb0120]).

To our knowledge, this is the first study that evaluates ToM functioning in patients with schizophrenia showing autistic traits. Results suggest that ATs+ group has a more pronounced ToM impairment, which mostly affects Cognitive ToM. Indeed, ANOVA shows significant differences between groups in PST Questionnaire Score and PST Total Score, while there is not a significant difference in PST Sequencing Score, which is considered a measure of Affective ToM. As observed by Bechi ([@bb0055]), Affective and Cognitive ToM deficits are differently distributed in schizophrenia. While Cognitive ToM resulted globally impaired compared with a healthy control group, Affective ToM seems to be more preserved in schizophrenia. Therefore, we could speculate that also patients with ATs are less impaired in Affective ToM then in cognitive ToM domain. Recently, a ToM functioning heterogeneity was also observed in ASD, with a different impairment of Affective and Cognitive ToM that can contribute to explain the severity of the illness ([@bb0005]). Our results are in line with this evidence, and we can hypothesize that ATs may contribute to explain the ToM functioning heterogeneity in schizophrenia, since ATs+ group presents a more pronounced impairment of ToM abilities.

Additionally, an intriguing result concerns functioning. As known, literature suggests multiple functional trajectories before schizophrenia onset, indeed during childhood and adolescence some patients do not show premorbid impairments, while others show a poor premorbid adjustment ([@bb0095]; [@bb0155]). Noteworthy, using PAS scale, we found significant differences between groups in premorbid paths and, in particular, a worse functioning during childhood and early adolescence in ATs+ group. These different functional trajectories are also observed, using QLS scale, in the current daily functioning. Indeed, ATs+ group shows a worse daily functioning, especially in Self-directedness. Surprisingly, we did not find differences in relationships domain; we can hypothesize that social skill differences did not emerge because it was assessed with the QLS task, which evaluates the subject\'s perception of his social functioning. It can be suggested that patients with ATs may show a different developmental trajectory since childhood, which seems to be more comparable to ASD\'s functional neurodevelopmental path, and a subsequent more impaired daily functioning. This relevant issue highlights the importance of early interventions for cognitive and social cognitive impairments, which may offer possible opportunity to modify the course of the disease in patients with ATs.

In sum, our results show that ATs+ group manifests lacking cognitive and ToM abilities, associated with the impairment in premorbid and current functioning. Taken together, these data suggest that patients with ATs may have specific neurodevelopmental features, which, however, do not meet diagnostic criteria for ASD.

Given this scenario, we evaluated the effect of rehabilitative interventions in patients with ATs, by estimating the effectiveness of a treatment aimed at enhancing ToM. Repeated measures ANOVA reveals a significant time × treatment interaction in the PST Total Score, and Post Hoc analyses show that the Schizophrenia group obtains a significant improvement after the training, while there is not significant enhancement in ATs+ group. Nevertheless, results show moderate to medium effects sizes for both groups in ToM first, second and third order beliefs, but not in PST Sequencing Score. This indeed suggests that a slight degree of improvement is achievable also in ATs+ group, particularly in Cognitive ToM domains. However, results show that both groups present an impairment of Affective ToM before the training, which can be enhanced only in in ATs− group. As sustained by literature, a good performance on PST Sequencing Task could be supported by cognitive abilities, such as executive functions ([@bb0125]; [@bb0255]), which resulted highly impaired in this group. The ATs+ present a wider impairment of high-level cognitive abilities which can be a limiting factor of ToM rehabilitation efficacy.

Therefore, it could be proposed that, even if ToM rehabilitative interventions produce a small improvement in ATs+ group, they do not provide the necessary building blocks for the acquirement of more complex abilities, suggesting that ATs limit the effectiveness of rehabilitation.

Indeed, this study has some limitations: the small sample size limits the generalizability of results and the study would have benefit from adding into analyses additional sociocognitive evaluations, such as Empathy and Emotion Recognition, and functional evaluations after the training. Moreover, studies suggested that ToM measures may not be sensitive enough to capture individual\'s ToM skills in real-life situations and thus may not be ecologically measures of mentalizing abilities.

In conclusion, this study suggests the existence of a distinct group of patients with schizophrenia exhibiting ATs that is characterized by a distinctive clinical, premorbid, functional, cognitive, and sociocognitive profile. To the best of our knowledge, few studies focused on these patients, and this is the first study specifically aimed at analyzing their sociocognitive abilities and premorbid functioning. Our results might have implications in clinical and rehabilitative practice; indeed we found that current rehabilitative interventions for ToM do not produce a significant ToM improvement, suggesting the importance of the implementation of cutting-edge, person-centered treatments, based on each subjects\' clinical and sociocognitive profile. Indeed, since the larger cognitive and sociocognitive impairment in ATs+ group, we can hypothesize that an integrated rehabilitative approach, including both ToM and neurocognitive interventions, can lead a ToM enhancement in both groups. Results suggest that PAUSS should be used more extensively in clinical practice, considering that not taking into account ATs may result in some patients not receiving appropriate services, benefits, or specific treatments.
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[^2]: PAUSS = PANSS Autism Severity Score (total score: range 0--56).

[^3]: Data are given as mean and (standard deviation).

[^4]: ANOVA = analysis of variance.

[^5]: PST = Picture Sequencing Task (Total Questionnaire Score: range 0--23; Total Sequencing Score: range 0--36; Total Score: range 0--59). I.Q. = Intelligence Quotient. BACS = Brief Assessment for Cognition in Schizophrenia (verbal memory: range 0--75; working memory: range 0--28; psychomotor speed and coordination: range 0--100; verbal fluency: 0--60; processing speed:0--110; executive functions: range 0--22). PAS = Premorbid Adjustment Scale (Total Score: range 0--1). QLS = Quality of Life Scale (Total Score: range 0--126).

[^6]: \* = p\<.05

[^7]: Data are given as mean and (standard deviation).

[^8]: PST = Picture Sequencing Task.

[^9]: Repeated measures (pre- to post-treatment changes) and interactions outcomes are reported.

[^10]: PST = Picture Sequencing Task.

[^11]: Significant within-group differences marked.

[^12]: Significant time and group × time interactions marked.
